Literature DB >> 32185681

Tislelizumab: First Approval.

Arnold Lee1, Susan J Keam2.   

Abstract

Tislelizumab (®;; Tileilizhu Dankang Zhusheye) is an anti-human programmed death receptor-1 (PD-1) monoclonal IgG4 antibody that is being developed by BeiGene as an immunotherapeutic, anti-neoplastic drug. Tislelizumab has been investigated in haematological cancers and advanced solid tumours, leading to its approval in December 2019 in China for patients with relapsed or refractory classical Hodgkin's lymphoma after at least second-line chemotherapy. This article summarises the major milestones in the development of tislelizumab for this first approval for classical Hodgkin's lymphoma, and its potential upcoming approvals in other indications.

Entities:  

Mesh：

Substances：

Year:  2020        PMID： 32185681     DOI： 10.1007/s40265-020-01286-z

Source DB:  PubMed          Journal:  Drugs        ISSN： 0012-6667            Impact factor:   9.546


  4 in total

1.  Pamiparib in combination with tislelizumab in patients with advanced solid tumours: results from the dose-escalation stage of a multicentre, open-label, phase 1a/b trial.

Authors:  Michael Friedlander; Tarek Meniawy; Ben Markman; Linda Mileshkin; Paul Harnett; Michael Millward; Joanne Lundy; Alison Freimund; Christie Norris; Song Mu; John Wu; Virginia Paton; Bo Gao
Journal:  Lancet Oncol       Date:  2019-08-01       Impact factor: 41.316

2.  The binding of an anti-PD-1 antibody to FcγRΙ has a profound impact on its biological functions.

Authors:  Tong Zhang; Xiaomin Song; Lanlan Xu; Jie Ma; Yanjuan Zhang; Wenfeng Gong; Yilu Zhang; Xiaosui Zhou; Zuobai Wang; Yali Wang; Yingdi Shi; Huichen Bai; Ning Liu; Xiaolong Yang; Xinxin Cui; Yanping Cao; Qi Liu; Jing Song; Yucheng Li; Zhiyu Tang; Mingming Guo; Lai Wang; Kang Li
Journal:  Cancer Immunol Immunother       Date:  2018-04-23       Impact factor: 6.968

Review 3.  FcγR-Binding Is an Important Functional Attribute for Immune Checkpoint Antibodies in Cancer Immunotherapy.

Authors:  Xin Chen; Xiaomin Song; Kang Li; Tong Zhang
Journal:  Front Immunol       Date:  2019-02-26       Impact factor: 7.561

4.  Treatment of relapsed or refractory classical Hodgkin lymphoma with the anti-PD-1, tislelizumab: results of a phase 2, single-arm, multicenter study.

Authors:  Yuqin Song; Quanli Gao; Huilai Zhang; Lei Fan; Jianfeng Zhou; Dehui Zou; Wei Li; Haiyan Yang; Ting Liu; Quanshun Wang; Fangfang Lv; Haiyi Guo; Liudi Yang; Rebecca Elstrom; Jane Huang; William Novotny; Vivian Wei; Jun Zhu
Journal:  Leukemia       Date:  2019-09-13       Impact factor: 11.528
  4 in total
  20 in total

Review 1.  Generation, secretion and degradation of cancer immunotherapy target PD-L1.

Authors:  Dan-Dan Shen; Ya-Ping Bi; Jing-Ru Pang; Li-Juan Zhao; Long-Fei Zhao; Ya Gao; Bo Wang; Hui-Min Liu; Ying Liu; Ning Wang; Yi-Chao Zheng; Hong-Min Liu
Journal:  Cell Mol Life Sci       Date:  2022-07-11       Impact factor: 9.207

2.  One case of comprehensive treatment for advanced liver cancer followed up over three years.

Authors:  Hai-Yan Liang; Qi-Lian Liang; Man Chen; Zhen-Wei Wang; Jie Huang
Journal:  Arch Med Sci       Date:  2022-06-23       Impact factor: 3.707

Review 3.  Experience with regorafenib in the treatment of hepatocellular carcinoma.

Authors:  Alessandro Granito; Antonella Forgione; Sara Marinelli; Matteo Renzulli; Luca Ielasi; Vito Sansone; Francesca Benevento; Fabio Piscaglia; Francesco Tovoli
Journal:  Therap Adv Gastroenterol       Date:  2021-05-28       Impact factor: 4.409

4.  Tislelizumab uniquely binds to the CC' loop of PD-1 with slow-dissociated rate and complete PD-L1 blockage.

Authors:  Yuan Hong; Yingcai Feng; Hanzi Sun; Bo Zhang; Hongfu Wu; Qing Zhu; Yucheng Li; Tong Zhang; Yilu Zhang; Xinxin Cui; Zhuo Li; Xiaomin Song; Kang Li; Mike Liu; Ye Liu
Journal:  FEBS Open Bio       Date:  2021-02-16       Impact factor: 2.693

5.  Case Report: Combination Therapy With PD-1 Blockade for Acute Myeloid Leukemia After Allogeneic Hematopoietic Stem Cell Transplantation Resulted in Fatal GVHD.

Authors:  Sun Yao; Chen Jianlin; Qiao Zhuoqing; Li Yuhang; Hu Jiangwei; Hu Guoliang; Ning Hongmei; Zhang Bin; Hu Liangding
Journal:  Front Immunol       Date:  2021-04-01       Impact factor: 7.561

Review 6.  Clinical outcomes and influencing factors of PD-1/PD-L1 in hepatocellular carcinoma.

Authors:  Jiting Wang; Jun Li; Guiju Tang; Yuan Tian; Song Su; Yaling Li
Journal:  Oncol Lett       Date:  2021-02-10       Impact factor: 2.967

7.  Tumor Flare Reaction in a Classic Hodgkin Lymphoma Patient Treated With Brentuximab Vedotin and Tislelizumab: A Case Report.

Authors:  Chunting Zhu; Yi Zhao; Fang Yu; Weijia Huang; Wenjun Wu; Jingsong He; Zhen Cai; Donghua He
Journal:  Front Immunol       Date:  2022-01-14       Impact factor: 7.561

Review 8.  Regorafenib Combined with Other Systemic Therapies: Exploring Promising Therapeutic Combinations in HCC.

Authors:  Alessandro Granito; Sara Marinelli; Antonella Forgione; Matteo Renzulli; Francesca Benevento; Fabio Piscaglia; Francesco Tovoli
Journal:  J Hepatocell Carcinoma       Date:  2021-05-26

9.  Tislelizumab in Asian patients with previously treated locally advanced or metastatic urothelial carcinoma.

Authors:  Dingwei Ye; Jiyan Liu; Aiping Zhou; Qing Zou; Hanzhong Li; Cheng Fu; Hailong Hu; Jian Huang; Shaoxing Zhu; Jie Jin; Lulin Ma; Jianming Guo; Jun Xiao; Se Hoon Park; Dahong Zhang; Xiusong Qiu; Yuanyuan Bao; Lilin Zhang; Wei Shen; Feng Bi
Journal:  Cancer Sci       Date:  2020-11-06       Impact factor: 6.518

10.  Case Report: THSD7A-Positive Membranous Nephropathy Caused by Tislelizumab in a Lung Cancer Patient.

Authors:  Minjiang Chen; Lei Zhang; Wei Zhong; Ke Zheng; Wei Ye; Mengzhao Wang
Journal:  Front Immunol       Date:  2021-05-10       Impact factor: 7.561
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.